Detalhe da pesquisa
1.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Cancer Sci
; 114(8): 3330-3341, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37183528
2.
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Int J Clin Oncol
; 28(1): 79-88, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36414827
3.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Cancer Sci
; 112(12): 5000-5010, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-34543477
4.
Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.
Jpn J Clin Oncol
; 51(1): 106-113, 2021 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33020837
5.
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Int J Clin Oncol
; 26(12): 2216-2223, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-34463869
6.
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Cancer Sci
; 111(2): 561-570, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31782583
7.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Cancer Sci
; 111(12): 4480-4489, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32926507
8.
Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.
J Oncol Pharm Pract
; 25(4): 865-868, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29651916
9.
Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
Cancer Sci
; 109(4): 1177-1184, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29363250
10.
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Cancer Sci
; 109(6): 1930-1938, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29697876
11.
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Cancer
; 124(19): 3830-3838, 2018 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30192383
12.
Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Cancer
; 124(3): 606-616, 2018 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29205286
13.
Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
Br J Cancer
; 118(1): 32-37, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29190637
14.
Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.
Invest New Drugs
; 36(3): 509-512, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29340837
15.
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Oncology
; 95(4): 251-256, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29902802
16.
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
BMC Cancer
; 18(1): 946, 2018 Oct 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30285770
17.
Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
BMC Cancer
; 18(1): 6, 2018 01 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29291705
18.
An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring.
Ther Drug Monit
; 40(6): 716-724, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30048380
19.
Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.
Pathol Int
; 68(3): 167-173, 2018 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-29341374
20.
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Int J Clin Oncol
; 22(1): 70-78, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27659294